This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Omnicell Gains 41.6% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
SYK Stock Gains on Launch of Hands-Free Device: Sync Badge
by Zacks Equity Research
Stryker's Sunc Badge is a Hands-free, wearable communication device that will support care team members with fast and reliable collaboration. It is likely to help offset the ongoing nurse shortage.
VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation
by Zacks Equity Research
Veeva Systems aims to enable advanced automation, including AI, for the life sciences industry via innovative technology and deep applications on the Veeva Vault Platform.
BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.
by Zacks Equity Research
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
by Zacks Equity Research
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
PHG Expands Enterprise Imaging in EU: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Philips expands cloud-based imaging in Europe, enhancing AI-driven workflows, collaboration and efficiency in radiology.
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
by Zacks Equity Research
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog The Goldman Sachs, The Progressive, Boston Scientific and Cooper-Standard
by Zacks Equity Research
The Goldman Sachs, The Progressive, Boston Scientific and Cooper-Standard are included in this Analyst Blog.
Top Stock Reports for Goldman Sachs, Progressive & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc. (GS), The Progressive Corporation (PGR) and Boston Scientific Corporation (BSX), as well as a micro-cap stock Cooper-Standard Holdings Inc. (CPS).
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
by Zacks Equity Research
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles
by Zacks Equity Research
Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its impressive long-term growth initiative.
Is PAHC Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging.
Boston Scientific (BSX) Stock Moves -0.75%: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed the most recent trading day at $100.80, moving -0.75% from the previous trading session.
XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down
by Zacks Equity Research
DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.
AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract
by Zacks Equity Research
Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.
MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the fourth quarter of 2024.
MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.